EYPT DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds EyePoint (NASDAQ: EYPT) Investors of Securities Class Action Lawsuit Deadline on January 19, 2027
NEW YORK CITY, NY / ACCESS Newswire / November 18, 2026 /If you purchased or acquired securities inEyePoint between May 27, 2025 and August 14, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ:EYPT) and reminds investors of the January 19, 2027 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) DURAVYU was less effective than Defendants had led investors to believe; (2) accordingly, DURAVYU 's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants ' public statements were materially false and misleading at all relevant times.
On August 17, 2026, EyePoint issued a press release announcing topline results from the LUGANO trial, disclosing that "the primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset, confounded by [an] asymmetric cohort." On this news, EyePoint 's stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026, on unusually heavy trading volume.
On October 19, 2026, EyePoint announced topline results from the LUCIA trial, disclosing that the trial also failed to meet its prespecified primary efficacy endpoint, and that EyePoint was initiating significant cost-cutting measures, including the immediate termination of its late-stage wet AMD clinical program and a 53% workforce reduction. On this news, EyePoint 's stock price fell $2.55 per share, or 85.28%, to close at $0.44 per share on October 19, 2026, on unusually heavy trading volume.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding EyePoint 's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the EyePoint class action, go to www.faruqilaw.com/EYPT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the EyePoint Securities Class Action Lawsuit:
What is the EyePoint securities fraud lawsuit about?
This securities class action alleges that EyePoint, Inc. and certain of its executives made materially false and misleading statements about DURAVYU, the company 's product candidate. The complaint alleges that DURAVYU was less effective than Defendants had led investors to believe. It further alleges that, as a result, DURAVYU 's clinical, regulatory, and commercial prospects were overstated. According to the complaint, Defendants ' public statements were therefore allegedly materially false and misleading at all relevant times.
Who may be eligible to participate in the lawsuit?
Investors who purchased EyePoint securities (NASDAQ:EYPT) between May 27, 2025 and August 14, 2026, inclusive, may be eligible to participate in the lawsuit. This period is referred to as the Class Period. Eligibility is based on the purchase of EyePoint securities during that time and the losses allegedly sustained as a result. Participation is not limited to those who apply to serve as lead plaintiff, and investors may be able to share in any recovery without taking that role.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a investor or group of investors appointed by the court to represent the interests of the class and to oversee the litigation, including the selection of counsel. Investors who wish to seek appointment as lead plaintiff must file a motion with the court by the lead plaintiff deadline of January 19, 2027. The court will then decide which movant is best suited to serve in that role. Investors do not need to serve as lead plaintiff to be eligible to share in any potential recovery, and they may remain absent class members.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased EyePoint securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE:Faruqi & Faruqi, LLP
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.












